

TABLE OF CONTENTS

LIST OF ABBREVIATIONS	v
1. INTRODUCTION	1
1.1. Breast Cancer	2
1.2. Strategies for breast cancer diagnosis	8
1.3. Treatment strategies for breast cancer	11
1.3.1. Surgery	12
1.3.2. Radiotherapy	13
1.3.3. Hormone Therapy	14
1.3.4. Chemotherapy	15
1.4. Multidrug Resistance	19
1.5 ABC transporter protein superfamily	21
1.6. Cellular mechanisms of multidrug resistance	24
1.7. Overcoming cellular multidrug resistance	26
1.8. Microenvironmental multidrug resistance	28
1.9. Targeting microenvironmental MDR	30
2. OBJECTIVES	33
3. MATERIALS and METHODS	34
3.1. In vitro experiments	34
3.1.1. Cell lines	34
3.1.2. Chemotherapeutics	34
3.1.3. Cytotoxicity analysis	34
3.1.4. Cell migration assay	35
3.1.5. Gene microarray analysis	36
3.1.6. Mammosphere formation assay	37
3.1.7. 3D tumor spheroid assay	37
3.1.8. Western blot analysis	38
3.1.9. Immunocytochemistry staining	39
3.2. Nanomedicine formulations	39
3.2.1. pHPMA polymers	39

3.2.2. Liposomes	39
3.2.3. Micelles	40
3.2.4. Nanogels	40
3.2.5. Doxil® (Caelyx®) and Abraxane®	42
3.3. In vivo experiments	42
3.3.1. Mouse model	42
3.3.2. In vivo and ex vivo imaging	42
3.3.3. Chemotherapy and nanotherapy treatment	44
3.4. Histological validation	45
3.4.1. Immunohistochemistry staining	45
3.4.2. Fluorescence microscopy	45
3.4.3. Flow cytometry	46
3.4.4. Two-photon laser scanning microscopy	46
3.4.5. Statistical analysis	47
4. RESULTS	48
4.1. Establishment of multidrug resistant 4T1 cells	48
4.2. Characterization of multidrug resistant 4T1 cells	55
4.2.1. Cell proliferation	55
4.2.2. Lysosomes	56
4.2.3. Epithelial to mesenchymal transition	57
4.2.4. Cell migration	59
4.2.5. Stem-like cell population	60
4.3. Overcoming cellular multidrug resistance with nanomedicines	65
4.3.1. Doxorubicin conjugated non-RGD and RGD-modified micelles	65
4.3.2. Treatment with doxorubicin-loaded PEGylated folate modified nanogels	68
4.4. Extracellular matrix remodeling features of multidrug resistant 4T1 cells	72
4.4.1. Analysis of 3D tumor spheroids	72
4.4.2. TGF- β pathway analysis	74
4.4.3. Gene microarray analysis	78
4.5. In vivo characterization of multidrug resistant 4T1 tumors	89
4.6. Nanoparticle delivery in multidrug resistant 4T1 tumor model	102

4.7. Overcoming MDR in multidrug resistant 4T1 tumor model	107
4.8. Microenvironment analysis in human breast tumor samples	114
5. DISCUSSION	116
6. SUMMARY	121
7. REFERENCES	123
8. APPENDIX	138
8.1. List of original publications	138
8.2. Acknowledgements	139
8.3. Erklärung zur Datenaufbewahrung	141
8.4. Erklärung über den Eigenanteil	142
8.5. Curriculum vitae	142